IDXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IDXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
IDEXX Laboratories's quarterly accounts payable & accrued expense declined from Jun. 2023 ($362 Mil) to Sep. 2023 ($355 Mil) but then increased from Sep. 2023 ($355 Mil) to Dec. 2023 ($395 Mil).
IDEXX Laboratories's annual accounts payable & accrued expense increased from Dec. 2021 ($372 Mil) to Dec. 2022 ($380 Mil) and increased from Dec. 2022 ($380 Mil) to Dec. 2023 ($395 Mil).
The historical data trend for IDEXX Laboratories's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Accounts Payable & Accrued Expense | Get a 7-Day Free Trial | 252.66 | 304.82 | 372.19 | 380.46 | 395.18 |
IDEXX Laboratories Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Accounts Payable & Accrued Expense | Get a 7-Day Free Trial | 380.46 | 391.26 | 361.80 | 354.87 | 395.18 |
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
James F Polewaczyk | officer: Corporate Vice President | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Jonathan Jay Mazelsky | director, officer: President and CEO | ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Martin Alexander Smith | officer: Executive Vice President | C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Jonathan W Ayers | director, officer: President & CEO | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Michael Lane | officer: Executive Vice President | C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092 |
Irene Chang Britt | director | CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103 |
Bruce L. Claflin | director | 7035 RIDGE ROAD, HANOVER MD 21076 |
Samer Abdul Samad | director | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Stuart Essig | director | 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Lawrence D Kingsley | director | C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062 |
Asha Collins | director | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
M Anne Szostak | director | C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837 |
Sharon E. Underberg | officer: EVP, GC & Corporate Secretary | EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650 |
Sophie V. Vandebroek | director | 6 OAK MEADOW ROAD, LINCOLN MA 01770 |
Daniel M Junius | director | C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By Business Wire • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.